History of Changes for Study: NCT05926960

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE)

A study version is represented by a row in the table.
Select two study versions to compare. One each from columns A and B.
Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
Click "Compare" to do the comparison and show the differences.
Select a version's Submitted Date link to see a rendering of the study for that version.
The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
Hover over the "Recruitment Status" to see how the study's recruitment status changed.
Study edits or deletions are displayed in red.
Study additions are displayed in green.

Study Record Versions

Version	Submitted Date	Changes
1	June 23, 2023	None (earliest Version on record)
2	July 16, 2023	Contacts/Locations and Study Status
3	August 15, 2023	Contacts/Locations and Study Status
4	September 8, 2023	Study Status and Contacts/Locations
5	October 6, 2023	Contacts/Locations and Study Status
6	November 18, 2023	Contacts/Locations and Study Status
7	December 21, 2023	Contacts/Locations and Study Status
8	January 3, 2024	Study Status, Contacts/Locations, Eligibility and Outcome Measures
9	February 11, 2024	Contacts/Locations and Study Status
10	March 17, 2024	Contacts/Locations and Study Status
11	April 5, 2024	Contacts/Locations and Study Status
12	April 19, 2024	Study Identification, Arms and Interventions and Study Status

Comparison Format:

Merged
Side-by-Side

Study Identification


Unique Protocol ID:	C4221023
Brief Title:	A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE)
Official Title:	A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DURING OR AFTER PRIOR TREATMENT WITH ANTI-PD-1 THERAPY
Secondary IDs:	2021-003640-24 [EudraCT Number] KEYNOTE PNC92 [Alias Study Number]

Study Status


Record Verification:	June 2023
Overall Status:	Recruiting
Study Start:	June 13, 2023
Primary Completion:	May 23, 2025 [Anticipated]
Study Completion:	May 23, 2027 [Anticipated]

First Submitted:	April 3, 2023
First Submitted that Met QC Criteria:	June 23, 2023
First Posted:	July 3, 2023 [Actual]

Last Update Submitted that Met QC Criteria:	June 23, 2023
Last Update Posted:	July 3, 2023 [Actual]

Sponsor/Collaborators


Sponsor:	Pfizer
Responsible Party:	Sponsor
Collaborators:	Merck Sharpe & Dohme LLC

Oversight


U.S. FDA-regulated Drug:	Yes
U.S. FDA-regulated Device:	No
Data Monitoring:

Study Description

Brief Summary:

The purpose of this study is to learn about the effects of 3 study medicines (encorafenib, binimetinib, pembrolizumab) compared to 2 study medicines (ipilimumab and nivolumab) given for the treatment of melanoma.

Melanoma is a type of cancer that starts in the cells that give color to your skin.

The study is seeking participants who:

have advanced or metastatic melanoma (has spread to other parts of the body);
have a certain abnormal gene called "BRAF".
have taken nivolumab or pembrolizumab treatment before this study.

Participants will either receive:

pembrolizumab given by intravenous infusion (directly into a vein) every 3 weeks at the study clinic. Participants will also receive encorafenib and binimetinib by mouth every day at home,
or will receive ipilimumab and nivolumab given by intravenous infusion (directly into a vein) every 3 weeks at the study clinic 4 times. This will be followed by nivolumab given by intravenous infusion every 4 weeks at the study clinic.

Both pembrolizumab and nivolumab will be given for a maximum of around 2 years. However, there is no time limit for encorafenib and binimetinib treatment.

The study team will see how each participant is doing after receiving the study treatments during regular visits to the study clinic.

Detailed Description:

The purpose of the study is to compare the efficacy of a triplet therapy (encorafenib, binimetinib, pembrolizumab) versus a doublet/control therapy (nivolumab and ipilimumab). Participants will have metastatic or unresectable locally advanced BRAF V600E/K-mutant melanoma, which progressed during or after prior treatment in the adjuvant or first-line metastatic setting, with an approved anti-PD-1 monotherapy (pembrolizumab or nivolumab),

Approximately 150 participants will be randomized in a 1:1 ratio to the triplet or the doublet/control therapy (75 participants in each arm). Randomization will be stratified by baseline serum LDH level, and by type of PD-1 resistance.

Conditions


Conditions:	Melanoma
Keywords:	BRAF BRAF V600E/K melanoma metastatic melanoma advanced melanoma skin cancer portside

Study Design


Study Type:	Interventional
Primary Purpose:	Treatment
Study Phase:	Phase 2
Interventional Study Model:	Parallel Assignment
Number of Arms:	2
Masking:	None (Open Label)
Allocation:	Randomized
Enrollment:	150 [Anticipated]

Arms and Interventions

Arms	Assigned Interventions
Experimental: Triplet encorafenib and binimetinib in combination with pembrolizumab	Drug: encorafenib encorafenib Other Names: BRAFTOVI Drug: binimetinib binimetinib Other Names: MEKTOVI Drug: pembrolizumab pembrolizumab Other Names: KEYTRUDA
Active Comparator: Doublet ipilimumab and nivolumab	Drug: ipilimumab ipilimumab Other Names: YERVOY Drug: nivolumab nivolumab Other Names: OPDIVO

Outcome Measures


Primary Outcome Measures:
1.	Objective Response Rate (ORR) is defined as the proportion of participants in each treatment arm with a confirmed best overall response of either Complete Response (CR) or Partial Response (PR), as determined by investigator assessment per RECIST v1.1 [ Time Frame: Time from the date of randomization to the earliest date disease progression, or start of subsequent anticancer therapy, or death due to any cause (assessed up to approximately 48 months). ]
Secondary Outcome Measures:
1.	Progression Free Survival in each treatment arm [ Time Frame: Time from the date of randomization to the earliest date of disease progression, as determined by investigator assessment per RECIST v1.1, or death due to any cause, whichever occurs first (assessed up to approximately 48 months) ]
2.	Overall Survival in each treatment arm [ Time Frame: Time from date of randomization to the date of death due to any cause or the last known alive date (assessed up to approximately 48 months) ]
3.	Duration of Response (CR or PR) in each treatment arm [ Time Frame: Time from the date of the first documented response (CR or PR) to the earliest date of disease progression, as determined by investigator assessment per RECIST v1.1, or death due to any cause (assessed up to approximately 48 months) ]
4.	Disease Control Rate (proportion of participants with a confirmed best overall response of CR, PR or SD) in each treatment arm [ Time Frame: Time from the date of randomization to the earliest date of disease progression, or start of subsequent anticancer therapy (assessed up to approximately 48 months) ]
5.	Time to Response (CR or PR) [ Time Frame: Time from the date of randomization to the date of first documented response (CR or PR), as determined by investigator assessment per RECIST v1.1 (assessed up to approximately 48 months) ]
6.	Progression Free Survival 2 in each treatment arm [ Time Frame: Time from date of randomization to date of discontinuation of next-line treatment after 1st disease progression, 2nd disease progression after initiation of next line treatment, or death due to any cause (assessed up to approximately 48 months) ]
7.	Incidence and severity of Adverse Events (AEs) and changes in clinical laboratory parameters, vital signs, and cardiac assessments. [ Time Frame: Time from first dose of study intervention through 28 days after the last dose of study intervention ] Number of participants with treatment emergent Adverse Events as as assessed per National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], version 4.03).
8.	Patient Reported Outcomes using EORTC QLQ-C30 questionnaires in each treatment arm [ Time Frame: Change from Baseline until Progressive Disease, death, withdrawal of consent, lost to follow-up, or end of study, whichever occurs first (assessed up to approximately 48 months) ] EORTC (European Organization for Research and Treatment of Cancer) QLQ-30 includes 5 functional scales (physical, role, emotional, cognitive and social functioning), 3 symptom scales (fatigue, nausea/vomiting, and pain), 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial impact) and a global health status/Quality of Life scale
9.	Patient Reported Outcomes using EuroQOL EQ-5D-5L questionnaires in each treatment arm [ Time Frame: Change from Baseline until Progressive Disease, death, withdrawal of consent, lost to follow-up, or end of study, whichever occurs first (assessed up to approximately 48 months) ] The EQ-5D-5L is a standardized measure of health utility that provides a single index value of health status and contains 1 item for each of 5 dimensions of HRQoL (ie, mobility, self-care, usual activities, pain or discomfort, and anxiety or depression).
10.	BRAF V600E/K Variant Allele Frequency and/or overall mean Variant Allele Frequency from circulating tumour DNA analysis in each treatment arm [ Time Frame: Change from baseline, and Day 1 of Cycles 2, 3, 5, 7 (a cycle is every 3 or 4 weeks), and End of Treatment (assessed up to approximately 48 months) ]

Eligibility


Minimum Age:	18 Years
Maximum Age:
Sex:	All
Gender Based:
Accepts Healthy Volunteers:	No
Criteria:	Inclusion Criteria: Male or female participants ≥18 years of age at the time of informed consent. Histologically confirmed unresectable (Stage IIIB, IIIC, or IIID) or metastatic (Stage IV) cutaneous melanoma, according to the AJCC 8th edition. Documented evidence of a BRAF V600E or V600K mutation. Submission of adequate tumor tissue for central laboratory testing of BRAF V600E-mutation and biomarkers is required for all participants during the screening period and prior to randomization. Must have received only 1 prior line of systemic therapy for melanoma (either adjuvant therapy or first-line anti-PD-1 monotherapy (ie, nivolumab or pembrolizumab) Must have anti-PD-1 resistant disease (primary or secondary) with confirmed disease progression per RECIST v1.1 either during or after receipt of an approved anti-PD-1 monotherapy (ie, nivolumab or pembrolizumab) for melanoma, defined according to the SITC Immunotherapy Resistance Taskforce (Kluger et al, 2020). Have at least one measurable lesion per RECIST v1.1. ECOG PS of 0-1, and adequate organ and cardiac function, including LVEF ≥50% by cardiac imaging. Exclusion Criteria: Mucosal or ocular melanoma. Diagnosis of immunodeficiency or an active autoimmune disease that required systemic treatment with chronic systemic steroid therapy or any other form of immunosuppressive therapy within the past 2 years. Clinically significant cardiovascular diseases. History of thromboembolic or cerebrovascular events ≤12 weeks prior to randomization. History or current evidence of RVO or current risk factors for RVO. Concurrent neuromuscular disorder that is associated with the potential of elevated CK. Active bacterial, fungal, or viral infection requiring systemic therapeutic treatment within 2 weeks prior to randomization. Current non-infectious pneumonitis/interstitial lung disease or history of noninfectious pneumonitis/interstitial lung disease requiring steroids. Prior or current symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases. Participants who permanently discontinued prior anti-PD-1 therapy due to toxicity or will be unable to tolerate combination therapy based on investigator judgement are excluded. Prior treatment with ipilimumab; prior combined immunotherapy blockade with anti-PD-1/L-1; prior treatment with a BRAFi and/or MEKi; or previous administration of an investigational anti-cancer agent for the adjuvant or first-line treatment of melanoma prior to randomization.

Contacts/Locations


Central Contact Person:	Pfizer CT.gov Call Center Telephone: 1-800-718-1021 Email: ClinicalTrials.gov_Inquiries@pfizer.com
Study Officials:	Pfizer CT.gov Call Center Study Director Pfizer
Locations:	Italy
	Istituto Nazionale Tumori IRCCS Fondazione Pascale [Not yet recruiting] Napoli, Italy, 80131
	Italy, Toscana
	Azienda Ospedaliero Universitaria Senese [Not yet recruiting] Siena, Toscana, Italy, 53100
	Poland
	Pratia MCM Krakow [Not yet recruiting] Krakow, Poland, 30-727
	Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy [Not yet recruiting] Warszawa, Poland, 02-781
	Slovakia
	Nemocnica na okraji mesta, n.o. [Not yet recruiting] Partizanske, Slovakia, 95801
	Spain
	Hospital General Universitario de Alicante [Not yet recruiting] Alicante, Spain, 03010
	Hospital Clínic de Barcelona [Not yet recruiting] Barcelona, Spain, 08036
	Hospital General Universitario Gregorio Marañon [Not yet recruiting] Madrid, Spain, 28007
	Hospital Universitario 12 de Octubre [Not yet recruiting] Madrid, Spain, 28041
	Hospital Universitario Virgen Macarena [Not yet recruiting] Sevilla, Spain, 41009
	Spain, Barcelona [barcelona]
	Hospital Universitari Vall d'Hebron [Recruiting] Barcelona, Barcelona [barcelona], Spain, 08035
	Spain, Valenciana, Comunitat
	Hospital General Universitario de Valencia [Not yet recruiting] Valencia, Valenciana, Comunitat, Spain, 46014

IPDSharing


Plan to Share IPD:	Yes Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
	Supporting Information:
	Time Frame:
	Access Criteria:
	URL: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests

References


Citations:
Links:	URL: https://pmiform.com/clinical-trial-info-request?StudyID=C4221023 Description: To obtain contact information for a study center near you, click here.
Available IPD/Information: